PMID- 20388104
OWN - NLM
STAT- MEDLINE
DCOM- 20100805
LR  - 20220309
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 16
IP  - 7
DP  - 2010
TI  - Risk profiles in type 2 diabetes (metabolic syndrome): integration of IL-10 
      polymorphisms and laboratory parameters to identify vascular damages related 
      complications.
PG  - 898-903
AB  - Recently it has been reported that low serum IL-10 levels are associated with an 
      increased susceptibility for metabolic syndrome and type 2 diabetes mellitus 
      (T2DM). We investigated whether the -1087G/A (rs1800896), -824C/T (rs1800871), 
      -597C/A (rs1800872) IL-10 polymorphisms were associated with type 2 diabetes in a 
      study on a cohort of Italian Caucasians comprising 490 type 2 diabetic and 349 
      control subjects. Stratifying the data according to IL-10 genotypes, trends for 
      the progressive increase of glucose and neutrophil levels were observed in 
      -1087GG vs. -1087GA vs. -1087AA positive diabetic patients 
      (-1087GG<-1087GA<-1087AA). In addition, evaluating the laboratory parameters 
      according to the -597/-824/-1087 derived haplotypes a significant increase of 
      neutrophils was found in diabetic vs. non-diabetic -597A/ -824T/-1087A positive 
      subjects (Student t test = 3.707, p<0.01). In an attempt to integrate clinical 
      laboratory and immunogenetic data to determine whether these factors taken 
      together define sufficient risk sets for type 2 diabetes we performed the 
      grade-of-membership analysis (GoM). GoM allowed to identify a population of 
      subjects negative for IL-10 -824T allele, 74.4% of which were diabetic patients 
      characterised by vascular damages (Chronic kidney failure and/or Myocardial 
      Infarction), reduction of haematocrit, increase of blood urea nitrogen, creatinin 
      and monocyte levels. These data seem to suggest that -597A/-824T/-1087A negative 
      subjects are more prone to the major type 2 diabetic vascular damages and allow 
      to hypothesise that the contemporary evaluation of some simple hematochemical 
      parameters and IL-10 SNPs may allow identifying diabetic patients with the worse 
      prognostic profile, needing both better complication prevention planning and 
      therapeutic strategies.
FAU - Forte, G I
AU  - Forte GI
AD  - Gruppo di studio sull'Immunosenescenza Dipartimento di Biopatologia e Metodologie 
      Biomediche, Universita di Palermo, 3Istituto di Calcolo e Reti ad Alta 
      Prestazione ICAR CNR, Palermo, Italy.
FAU - Pilato, G
AU  - Pilato G
FAU - Vaccarino, L
AU  - Vaccarino L
FAU - Sanacore, M
AU  - Sanacore M
FAU - Candore, G
AU  - Candore G
FAU - Romano, G C
AU  - Romano GC
FAU - Testa, R
AU  - Testa R
FAU - Franceschi, C
AU  - Franceschi C
FAU - Capri, M
AU  - Capri M
FAU - Marra, M
AU  - Marra M
FAU - Bonfigli, A R
AU  - Bonfigli AR
FAU - Caruso, C
AU  - Caruso C
FAU - Scola, L
AU  - Scola L
FAU - Lio, D
AU  - Lio D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Blood Glucose)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Cohort Studies
MH  - Diabetes Complications/*genetics
MH  - Diabetes Mellitus, Type 2/*genetics
MH  - Female
MH  - Haplotypes/genetics
MH  - Humans
MH  - Interleukin-10/*genetics
MH  - Kidney Failure, Chronic/*diagnosis/genetics
MH  - Male
MH  - Metabolic Syndrome/*complications
MH  - Middle Aged
MH  - Myocardial Infarction/*diagnosis/genetics
MH  - Neutrophils/metabolism
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Risk Factors
EDAT- 2010/04/15 06:00
MHDA- 2010/08/06 06:00
CRDT- 2010/04/15 06:00
PHST- 2009/10/01 00:00 [received]
PHST- 2009/10/29 00:00 [accepted]
PHST- 2010/04/15 06:00 [entrez]
PHST- 2010/04/15 06:00 [pubmed]
PHST- 2010/08/06 06:00 [medline]
AID - Jirillo 17 [pii]
AID - 10.2174/138161210790883642 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2010;16(7):898-903. doi: 10.2174/138161210790883642.